Energy metabolism
NAD+/NADH cycling is central to reactions that help cells transfer energy from nutrients. This does not mean NMN acts as an immediate stimulant.
NMN and NAD+ evidence centre
The Science of NMN and NAD+
A plain-language guide to what nicotinamide mononucleotide is, how it relates to NAD+, what human trials have measured, where evidence remains uncertain and how Canadian shoppers can evaluate product labels, licences and laboratory documentation.
Plain-language summary
What the evidence currently supports
- NMN is an intermediate in biological pathways that produce NAD+, a coenzyme involved in energy-transfer reactions and enzyme activity.
- Several small human trials report that oral NMN can raise NAD+ or related metabolites in blood.
- Some trials report changes in selected outcomes such as muscle insulin sensitivity or exercise-related measures, but results are not universal.
- Available human trials are generally short and small. They do not establish that NMN reverses ageing, prevents disease or extends human lifespan.
The basics
NMN is not NAD+—it is one precursor in the NAD+ network
NUNMN’s educational material describes NMN as a precursor to NAD+. In biochemical terms, NMN can be converted into NAD+ through enzymatic steps. NAD+ then participates in redox reactions and also serves as a substrate for enzymes including sirtuins and PARPs.
Vitamin B3-related inputsNicotinamide, nicotinic acid, nicotinamide riboside and tryptophan can contribute through different pathways.
NMNNicotinamide mononucleotide is a late-stage intermediate in NAD+ biosynthesis.
NAD+A coenzyme used in energy-transfer reactions and as a substrate by NAD+-consuming enzymes.
DNA-maintenance enzymes
PARP enzymes consume NAD+ during DNA-damage responses. A pathway role is not proof that a supplement repairs DNA or prevents disease.
Cell signalling
Sirtuins and other NAD+-dependent enzymes are studied in metabolism and ageing biology. Much mechanistic evidence remains preclinical.
Dynamic regulation
NAD+ availability is influenced by synthesis, recycling, diet, tissue, disease state and the activity of enzymes that consume it.
Evidence hierarchy
Why human, animal and laboratory findings must be separated
NUNMN’s science pages discuss mechanisms and animal findings alongside human research. These categories answer different questions and should not be presented as if they provide the same level of evidence.
Human clinical studies
These studies test a specific dose, population and period. Current NMN trials are generally small and short, so they are useful but not definitive.
Animal studies
Animal models help researchers test mechanisms and long-term hypotheses. Their outcomes cannot be assumed to occur in humans.
Cell and laboratory studies
Controlled experiments can show pathway activity or molecular effects. They do not establish real-world benefit, dose or safety in people.
Human clinical evidence
What selected human NMN trials found
The table summarizes representative primary studies. It is not a claim that a NUNMN product will reproduce a research result: trial materials, populations, dosing, duration and endpoints may differ from retail products and individual use.
| Study | Design | Dose and duration | Main reported finding | Important limitation |
|---|---|---|---|---|
| Irie et al., 2020 Human |
Single-arm dose-escalation study in 10 healthy men | Single doses of 100, 250 and 500 mg | No significant acute clinical symptoms or major measured safety changes were reported during the short observation period. | Very small, male-only and designed for short-term safety rather than effectiveness. |
| Yoshino et al., 2021 Human RCT |
Randomized, double-blind, placebo-controlled trial in postmenopausal women with prediabetes | 250 mg daily for 10 weeks | Muscle insulin sensitivity and selected muscle signalling measures improved compared with placebo. | Narrow population; findings do not establish the same effect in healthy adults or long-term disease outcomes. |
| Liao et al., 2021 Human RCT |
Randomized, double-blind, four-arm trial in 48 recreational runners | 300, 600 or 1,200 mg daily with training for 6 weeks | Some ventilatory-threshold and oxygen-utilization measures improved in the medium- and high-dose groups. | Short study in trained runners; several performance measures, including peak VO₂max, did not differ. |
| Okabe et al., 2022 Human RCT |
Randomized, double-blind, placebo-controlled trial in 30 healthy adults | 250 mg daily for 12 weeks | Whole-blood NAD+ increased; the intervention was generally tolerated during the study period. | Small sample, short follow-up and no broad improvement in weight, blood pressure or pulse. |
| Katayoshi et al., 2023 Human RCT |
Randomized, double-blind, placebo-controlled trial in 36 healthy middle-aged adults | 250 mg daily for 12 weeks | Some NAD-related metabolites changed; arterial-stiffness values only tended to improve and were not significantly different between groups. | Small study with exploratory outcomes; a trend is not proof of clinical benefit. |
What these studies do not prove
They do not show that NMN reverses human ageing, extends lifespan, prevents cancer, treats diabetes, repairs DNA throughout the body or replaces established medical care. A biomarker change is not automatically a meaningful health outcome.
NUNMN product context
How NUNMN describes its NMN products
NUNMN states that its NMN is produced using a biological enzyme method, is tested to a stated purity of 99.5%, and is manufactured in facilities following GMP standards. Its FAQ also describes the capsules as free from nuts, gluten, animal by-products, artificial colours and artificial flavours.
These are brand and manufacturing statements, not clinical evidence. They should be checked against the exact bottle label, product-specific licence and a readable lot-specific Certificate of Analysis before being repeated for an individual SKU.
- Purity: look for an assay result tied to the product and lot.
- Identity: confirm that the laboratory tested the stated compound, not only total weight.
- Contaminants: review heavy-metal and microbial testing where available.
- Storage: follow the exact label; NUNMN advises a cool, dry place away from direct sunlight.
Formula context
NUNMN NMN formats currently referenced by this store
Product names do not indicate stronger science. Compare the amount per capsule, capsule count and complete ingredient profile. Availability and package options should be confirmed on each product page.
NMN 15000 combination
250 mg NMN + 50 mg CoQ10 + 50 mg resveratrol per capsule · 60 capsules.
View product details →
Canadian regulatory context
An NPN applies to an exact licensed product—not an entire catalogue
Health Canada’s current record for NPN 80114685 identifies a 300 mg NMN capsule, lists the brand names “NMN,” “NMN 1800” and “NMN 9000,” and names Viker Company Group Ltd. as the licence holder. The authorized purpose is “Source of Vitamin B3, a factor in the maintenance of good health.”
NUNMN’s FAQ refers generally to NPN 80114685. For accuracy, shoppers should match the exact brand name, medicinal ingredient, strength, dosage form, directions and warnings on the bottle to the official record. The same NPN should not automatically be displayed for a 500 mg capsule, combination formula, NAC product, shilajit product or testing service.
Safety and use
Short-term tolerability is not the same as proven long-term safety
Small human studies have tested doses from 100 mg to more than 1,000 mg under research conditions. Many report no serious treatment-related safety signal during short study periods, but that does not establish an ideal dose or long-term safety for every person.
- Follow the exact product label: research doses do not replace labelled directions.
- Pregnancy and breastfeeding: do not use products whose label contraindicates use; seek professional advice.
- Diabetes: the Health Canada record for NPN 80114685 advises consulting a healthcare practitioner before use.
- Medication and health conditions: ask a pharmacist or qualified clinician about interactions and suitability.
- Stop and seek advice: discontinue use if you experience persistent or concerning symptoms.
How to evaluate a claim
Six questions to ask before trusting NMN marketing
1. Was the evidence human?
Cell and animal findings are useful for hypotheses, but should not be presented as confirmed outcomes in people.
2. Was the study controlled?
Randomization, blinding and a placebo group reduce bias, although they do not remove every limitation.
3. Was the result clinically meaningful?
A statistically significant biomarker change may not translate into better health, function or quality of life.
4. Does the product match the study?
Compare ingredient identity, dose, formulation, schedule and duration rather than assuming all NMN products are interchangeable.
5. Is the licence product-specific?
Match the exact label to Health Canada’s database. One NPN cannot be used as a catalogue-wide badge.
6. Can the COA be matched to the lot?
A useful COA identifies the product, lot, laboratory, test date, method and measured results.
Glossary
Key terms used in NMN research
- NMN
- Nicotinamide mononucleotide, an intermediate used in biological pathways that produce NAD+.
- NAD+
- Nicotinamide adenine dinucleotide, a coenzyme involved in redox reactions and enzyme activity.
- Precursor
- A substance that can be converted through one or more steps into another compound.
- Biomarker
- A measurable biological indicator. A biomarker change is not automatically a health benefit.
- Randomized controlled trial
- A study that assigns participants to groups by chance and compares an intervention with a control.
- NPN
- An eight-digit Natural Product Number assigned by Health Canada to an exact licensed natural health product.
- COA
- A Certificate of Analysis reporting tests performed on an ingredient or finished-product lot.
- Assay
- A laboratory measurement used to estimate the identity, amount or purity of a tested substance.
- Preclinical
- Research performed in cells, laboratory systems or animals before or outside human clinical testing.
Primary references
Human studies and official records used on this page
Study links lead to the publication record or full text. The references are provided for transparency and do not imply that every result applies to every product or person.
- Irie J, et al. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. PubMed record.
- Yoshino M, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. PubMed record.
- Liao B, et al. (2021). Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. Full text.
- Okabe K, et al. (2022). Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood NAD+ levels in healthy subjects. Full text.
- Katayoshi T, et al. (2023). Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term NMN supplementation. Full text.
- Health Canada. Licensed Natural Health Products Database record for NPN 80114685. Official product record.
- NUNMN. Current science, FAQ and product pages used for brand statements, capsule strengths and formulation context. NUNMN science page and NUNMN FAQ.
Science FAQ
Common questions about NMN evidence
Is NMN the same as NAD+?
No. NMN is an intermediate that the body can use in pathways that produce NAD+. NAD+ is the coenzyme used in many cellular reactions.
Does human research show that NMN raises NAD+?
Several small trials report increases in blood NAD+ or related metabolites after oral NMN. Results depend on the study population, dose, sample type and laboratory method.
Has NMN been proven to reverse ageing?
No. Human trials have not established that NMN reverses biological ageing, extends lifespan or prevents age-related disease.
Are animal results relevant to people?
Animal studies help researchers understand mechanisms and decide what to test next, but they cannot be treated as proof of the same result in humans.
Is a higher NMN dose automatically better?
No. A higher amount per capsule is a format difference, not proof of greater benefit. Follow the exact label and seek professional advice when appropriate.
Does NPN 80114685 apply to every NUNMN product?
No. Health Canada’s record is for a specific 300 mg NMN capsule. The exact product label must match the licence record; it should not be extended automatically to other strengths, combination formulas or non-NMN products.
What does NUNMN's 99.5% purity statement mean?
It is a brand quality statement that should be supported by an appropriate assay and lot-specific laboratory report. Purity alone does not establish clinical effectiveness, stability or contaminant testing.
Can NMN replace sleep, exercise or medical care?
No. Supplements do not replace adequate sleep, physical activity, nutrition, risk-factor management, prescribed treatment or advice from a qualified healthcare professional.
Use the evidence before choosing a product
Compare the exact amount per capsule, complete ingredient list, product-specific licence, labelled directions and lot documentation. Product pages contain the current package and checkout information; this science page remains educational.
Scientific and medical disclaimer: This page is for general education and does not diagnose, treat, cure or prevent disease. Human NMN research remains limited and is not proof that a retail supplement will produce a specific outcome. Read the complete product label and consult a qualified healthcare professional before use, especially if you are pregnant, breastfeeding, taking medication, living with diabetes or another medical condition, preparing for surgery or receiving cancer treatment.